📗 Cite This Artifact
Japan Neurodegeneration Epidemiology
Japan Neurodegeneration Epidemiology
Overview
Japan represents the world's most advanced "super-aging" society, providing unique insights into neurodegenerative disease epidemiology:
- 29% of population aged 65+ (highest globally)
- 15% aged 75+ ("late-stage aging society")
- World-leading life expectancy (84 years)
- Excellent healthcare infrastructure enabling comprehensive data collection
- Cultural factors affecting diagnosis and care
Alzheimer's Disease
Prevalence (2025)
| Age Group | Prevalence Rate | Number Affected |
|-----------|-----------------|-----------------|
| 65-69 years | ~4-5% | ~1.5 million |
| 70-74 years | ~8-10% | ~2.5 million |
| 75-79 years | ~15-18% | ~3 million |
| 80-84 years | ~25-28% | ~3 million |
| 85+ years | ~35-40% | ~2.5 million |
| Total (65+) | ~15-17% | ~7 million |
| Total (all ages) | ~5.5% | ~7 million |
Key Characteristics:
- Highest age-standardized prevalence globally
- Very high proportion of oldest-old (85+) in population
- Female predominance (2:1) due to longer life expectancy
Projections
| Year | Projected Cases | % of Population |
|------|-----------------|-----------------|
| 2025 | 7 million | 5.7% |
| 2030 | 8 million | 6.8% |
| 2040 | 9 million | 8.2% |
| 2050 | 10 million | 9.5% |
Note: Despite peak aging around 2040, absolute numbers continue rising due to population decline at younger ages.
Regional Distribution
...
Japan Neurodegeneration Epidemiology
Overview
Japan represents the world's most advanced "super-aging" society, providing unique insights into neurodegenerative disease epidemiology:
- 29% of population aged 65+ (highest globally)
- 15% aged 75+ ("late-stage aging society")
- World-leading life expectancy (84 years)
- Excellent healthcare infrastructure enabling comprehensive data collection
- Cultural factors affecting diagnosis and care
Alzheimer's Disease
Prevalence (2025)
| Age Group | Prevalence Rate | Number Affected |
|-----------|-----------------|-----------------|
| 65-69 years | ~4-5% | ~1.5 million |
| 70-74 years | ~8-10% | ~2.5 million |
| 75-79 years | ~15-18% | ~3 million |
| 80-84 years | ~25-28% | ~3 million |
| 85+ years | ~35-40% | ~2.5 million |
| Total (65+) | ~15-17% | ~7 million |
| Total (all ages) | ~5.5% | ~7 million |
Key Characteristics:
- Highest age-standardized prevalence globally
- Very high proportion of oldest-old (85+) in population
- Female predominance (2:1) due to longer life expectancy
Projections
| Year | Projected Cases | % of Population |
|------|-----------------|-----------------|
| 2025 | 7 million | 5.7% |
| 2030 | 8 million | 6.8% |
| 2040 | 9 million | 8.2% |
| 2050 | 10 million | 9.5% |
Note: Despite peak aging around 2040, absolute numbers continue rising due to population decline at younger ages.
Regional Distribution
- Okinawa: Highest longevity, highest dementia prevalence
- Northern regions (Hokkaido, Tohoku): Higher rates
- Urban areas (Tokyo, Osaka): Better diagnosis, higher reported rates
Economic Burden
| Category | Annual Amount (JPY) | USD Equivalent |
|----------|---------------------|----------------|
| Medical costs | ~¥3 trillion | ~$20 billion |
| Long-term care | ~¥8 trillion | ~$53 billion |
| Informal care | ~¥4 trillion | ~$27 billion |
| Total | ~¥15 trillion | ~$100 billion |
| Per-patient cost | ~¥2 million | ~$13,000 |
Parkinson's Disease
Prevalence (2025)
| Age Group | Prevalence Rate | Number Affected |
|-----------|-----------------|-----------------|
| 50-59 years | ~0.3-0.5% | ~200,000 |
| 60-69 years | ~0.8-1.0% | ~400,000 |
| 70-79 years | ~1.5-2.0% | ~500,000 |
| 80+ years | ~2-3% | ~200,000 |
| Total (50+) | ~1.3% | ~1.3 million |
Notes:
- Lower reported prevalence than Western countries
- Strong genetic research (LRRK2, GBA studies in Japanese population)
- Possible protective genetic factors being investigated
Projections
| Year | Projected Cases |
|------|-----------------|
| 2025 | 1.3 million |
| 2030 | 1.5 million |
| 2040 | 1.8 million |
| 2050 | 2.0 million |
Economic Burden
| Category | Annual Amount (JPY) | USD Equivalent |
|----------|---------------------|----------------|
| Direct medical | ~¥500 billion | ~$3.3 billion |
| Caregiving | ~¥1 trillion | ~$6.7 billion |
| Lost productivity | ~¥500 billion | ~$3.3 billion |
| Total | ~¥2 trillion | ~$13 billion |
Amyotrophic Lateral Sclerosis (ALS)
Prevalence (2025)
| Metric | Value |
|--------|-------|
| Total cases | ~8,000-10,000 |
| Annual new cases | ~1,000-1,500 |
| Annual deaths | ~1,200-1,500 |
| Median survival | 2-4 years |
Characteristics:
- Higher incidence of bulbar-onset ALS
- Strong research on SOD1, FUS, C9orf72
- Excellent patient registries (JALSDC)
Frontotemporal Dementia (FTD)
Prevalence (2025)
| Metric | Estimated Value |
|--------|-----------------|
| Total cases | ~20,000-30,000 |
| Mean age at onset | 50-55 years |
| Underdiagnosis | Significant |
Genetic Profile:
- Different from Western populations
- Less C9orf72 expansion
- More TARDBP mutations reported
Other Neurodegenerative Disorders
Parkinson's Plus Syndromes
| Disorder | Estimated Cases |
|----------|-----------------|
| MSA | ~5,000-8,000 |
| PSP | ~8,000-12,000 |
| CBS | ~3,000-5,000 |
Dementia with Lewy Bodies (DLB)
| Metric | Value |
|--------|-------|
| Estimated cases | ~100,000-150,000 |
| % of dementia | ~10-15% |
Long-Term Care System
Japan's unique long-term care insurance system (Kaigo Hoken, 2000) provides:
- Level 1-5 care needs: Certified assessment system
- Home care services: Up to ¥350,000/month maximum
- Facility care: Nursing homes, group homes
- Cash benefits: Optional direct payment to families
- ~6.5 million people certified as needing care
- ~3.5 million using services
- Dementia is leading cause of certification (26%)
Research Infrastructure
- J-ADNI: Japanese Alzheimer's Disease Neuroimaging Initiative
- J-PD: Japanese Parkinson's disease registry
- Brain Bank Network: Multiple brain banks for research
- Biobank Japan: Large-scale genetic database
Policy Response
- Orange Plan (2005): Dementia countermeasures
- New Orange Plan (2015): Enhanced measures
- Promotion of Comprehensive Dementia Care: 2023+ initiatives
- Dementia-friendly Community: Regional programs nationwide
Summary: Japan Neurodegeneration Burden
| Disease | Prevalence (2025) | Projected 2050 | Economic Cost |
|---------|-------------------|----------------|---------------|
| Alzheimer's Disease | 7 million | 10 million | ~$100 billion |
| Parkinson's Disease | 1.3 million | 2 million | ~$13 billion |
| ALS | 8,000-10,000 | Stable | ~$500 million |
| FTD | 20,000-30,000 | 40,000+ | ~$2 billion |
| DLB | 100,000-150,000 | 200,000+ | ~$10 billion |
Key Challenges:
Cross-Links
- [Neurodegeneration Impact Measures](/diseases/neurodegeneration-impact-measures)
- [Japan Neuroscience Society](/institutions/japan-neuroscience-society)
- [Epidemiology of Neurodegenerative Diseases](/diseases/epidemiology-neurodegenerative-diseases)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
References
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | diseases-japan-neurodegeneration-epidemiology |
| kg_node_id | None |
| entity_type | disease |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-9c0b04d7aad8 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'diseases-japan-neurodegeneration-epidemiology'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-diseases-japan-neurodegeneration-epidemiology?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Japan Neurodegeneration Epidemiology](http://scidex.ai/artifact/wiki-diseases-japan-neurodegeneration-epidemiology)
http://scidex.ai/artifact/wiki-diseases-japan-neurodegeneration-epidemiology